Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
385.00    0.00 (0.00%)
Bid:
380.00
Ask:
390.00
Spread: 10.00 (2.632%)
Market Cap: £184.79m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Directorate Change

2 Jun 2010 07:00

RNS Number : 9010M
Tristel PLC
02 June 2010
 



 

("Tristel" or the "Company")

AIM: TSTL

 

Board Changes

 

Tristel plc, the AIM listed provider of infection and contamination control products, announces the appointment of Elizabeth Dixon as finance director. Ms Dixon replaces Paul Barnes who has been part-time group finance director since before the Company's flotation in June 2005. Mr Barnes continues on the Board as non-executive chairman of the Audit Committee. 

 

Ms Dixon, aged 40, is an experienced financial and management accountant having held senior finance roles for the past 10 years. She has acted as Tristel's group chief accountant since July 2007 and was appointed as finance director of the main trading subsidiary Tristel Solutions Limited in August 2009.

 

Ms Dixon is currently interested in 1,009 Ordinary 1p Shares, representing less than 1 per cent of the Company's issued share capital. In addition she holds options over 120,000 ordinary shares of 1p each in the Company ("Shares") under the Tristel plc Enterprise Management Incentive Scheme 2005 (the "Scheme"). 45,000 of these options are currently exercisable at 53.75p per share, further tranches of 15,000 options are exercisable at 53.75p on each of the following dates, 23rd July 2010, 4th August 2010, 23rd July 2011, 4th August 2011 and 4th August 2012

 

Pursuant to Rule 17, Schedule Two (g) of the AIM Rules for Companies the following information is disclosed:

 

Current Appointments of Elizabeth Dixon

Tristel Solutions Limited

 

Previous Appointments

None

 

ENDS

 

For further information, please contact:

Tristel PLC

 

Paul Swinney, Chief Executive

Tel: 01638 721 500

 

 

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

 

paul.mcmanus@walbrookpr.com

 

 

FinnCap

 

Geoff Nash/Rhydian Bankes (Corporate Finance)

Tel: 020 7600 1658

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEAXKFELLEEFF
Date   Source Headline
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
31st Mar 20258:56 amRNSHolding(s) in Company
26th Mar 202510:30 amRNSDirector/PDMR Shareholding
18th Mar 20252:39 pmRNSHolding(s) in Company
24th Feb 20257:00 amRNSUnaudited Interim Results
7th Feb 20257:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20257:00 amRNSDirector Option Grant
13th Jan 20257:00 amRNSConfirmation of Interim Results
16th Dec 20242:45 pmRNSResult of AGM
16th Dec 20247:00 amRNSAGM Statement and Notice of Interim Results
22nd Nov 202410:30 amRNSNotice of AGM & Posting of Annual Report &Accounts
21st Nov 20241:32 pmRNSExercise of Share Options and Total Voting Rights
20th Nov 20248:47 amRNSExercise of Share Options and Total Voting Rights
28th Oct 20241:37 pmRNSExercise of Share Options and Total Voting Rights
21st Oct 20247:00 amRNSFinal Results
1st Oct 20247:00 amRNSNotice of Preliminary Results
20th Sep 20247:00 amRNSDirector/PDMR Shareholding
19th Sep 20241:13 pmRNSExercise of Share Options and Total Voting Rights
12th Sep 20247:00 amRNSFDA 510(k) submission for Tristel OPH
2nd Sep 20247:00 amRNSConfirmation of CEO Transition, Directorate Change
6th Aug 20243:32 pmRNSExercise of Share Options and Total Voting Rights
22nd Jul 20247:00 amRNSTrading Update
4th Jul 20243:43 pmRNSExercise of Share Options and Total Voting Rights
11th Jun 20245:48 pmRNSDirector/PDMR Shareholding
11th Jun 20243:50 pmRNSHolding(s) in Company
10th Jun 20247:00 amRNSAppointment of CEO
8th May 20247:00 amRNSTristel™ ULT case study
7th May 20247:00 amRNSExercise of Share Options and Total Voting Rights
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.